F-group (family)
208.1.1.3 Hexapep,Acetyltransf_11
Ligands and drugs
471
Member domains
230
with ligand contacts (≤ 4 Å)
48.8% of members
230
with DrugDomain annotations
48.8% of members
133
with a DrugBank compound
28.2% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 208.1.1.3 belongs to X-group 208 Single-stranded left-handed beta-helix, which binds 8.7 ligand superclasses per 20 proteins, broader than 71% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03397 | UD1 | Uridine-Diphosphate-N-Acetylglucosamine | 7 |
| DB03556 | PE5 | 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400 | 4 |
| DB08558 | SOG | 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL | 1 |
| DB09459 | TLA | L-tartaric acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 40 |
| VFE | 2-[2-(2-chlorophenyl)sulfanylethanoyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-methyl-ethanamide | 34 |
| VFN | ~{N}-[(5-azanyl-1,3,4-oxadiazol-2-yl)methyl]-2-(2-chlorophenyl)sulfanyl-~{N}-[(4-cyanophenyl)methyl]ethanamide | 33 |
| VFT | 2-(2-chlorophenyl)sulfanyl-~{N}-[(4-cyanophenyl)methyl]-~{N}-(1~{H}-imidazol-4-ylmethyl)ethanamide | 30 |
| VFZ | ~{N}-[(5-azanyl-1,3,4-oxadiazol-2-yl)methyl]-2-(2-chlorophenyl)sulfanyl-~{N}-[(6-oxidanylidene-1~{H}-pyridin-3-yl)methyl]ethanamide | 30 |
| UD1 | URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE | 7 |
| F30 | 3-bromo-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-5-carboxamide | 6 |
| F3R | N~2~-(cyclohexylacetyl)-N-1H-tetrazol-5-yl-L-alaninamide | 6 |
| F4L | Nalpha-(tert-butoxycarbonyl)-N-1H-tetrazol-5-yl-D-tryptophanamide | 6 |
| F6I | (4S)-N-(1H-tetrazol-5-yl)-2-[3-(trifluoromethyl)benzene-1-sulfonyl]-1,2,3,4-tetrahydroisoquinoline-4-carboxamide | 6 |
| F9H | (3S)-3-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)-N-(1H-tetrazol-5-yl)-1-[3-(trifluoromethyl)benzoyl]-2,3-dihydro-1H-indole-3-carboxamide | 6 |
| FCU | (3S)-3-({[(Z)-phenylmethylidene]carbamoyl}amino)-N-(1H-tetrazol-5-yl)-1-[3-(trifluoromethyl)benzoyl]-2,3-dihydro-1H-indole-3-carboxamide | 6 |
| Q5G | 3-({2-[(2R)-2-carbamoyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl]-2-oxoethyl}sulfanyl)propanoic acid | 6 |
| Q5M | 4-(naphthalen-1-yl)-4-oxobutanoic acid | 6 |
| U21 | uridine-5'-diphosphate-3-O-(R-3-hydroxydecanoyl)-N-acetyl-D-glucosamine | 6 |
| CAmetal | CALCIUM ION | 5 |
| U20 | uridine-5'-diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetyl-D-glucosamine | 5 |
| PE5 | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL | 4 |
| PG0 | 2-(2-METHOXYETHOXY)ETHANOL | 3 |
| S2N | S-[2-({N-[(2R)-2-hydroxy-4-{[(S)-hydroxy(methoxy)phosphoryl]oxy}-3,3-dimethylbutanoyl]-beta-alanyl}amino)ethyl] (3R)-3-hydroxydodecanethioate | 3 |